WO2006127514A3 - Compositions and methods for treating hiv infection with cupredoxin and cytochrome c - Google Patents

Compositions and methods for treating hiv infection with cupredoxin and cytochrome c Download PDF

Info

Publication number
WO2006127514A3
WO2006127514A3 PCT/US2006/019565 US2006019565W WO2006127514A3 WO 2006127514 A3 WO2006127514 A3 WO 2006127514A3 US 2006019565 W US2006019565 W US 2006019565W WO 2006127514 A3 WO2006127514 A3 WO 2006127514A3
Authority
WO
WIPO (PCT)
Prior art keywords
cupredoxin
cytochrome
infection
methods
compositions
Prior art date
Application number
PCT/US2006/019565
Other languages
French (fr)
Other versions
WO2006127514A2 (en
Inventor
Ananda Chakrabarty
Tapas Das Gupta
Tohru Yamada
Anita Chaudhari
Arsenio Fialho
Chang Soo Hong
Original Assignee
Univ Illinois
Ananda Chakrabarty
Tapas Das Gupta
Tohru Yamada
Anita Chaudhari
Arsenio Fialho
Chang Soo Hong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/244,105 external-priority patent/US7691383B2/en
Application filed by Univ Illinois, Ananda Chakrabarty, Tapas Das Gupta, Tohru Yamada, Anita Chaudhari, Arsenio Fialho, Chang Soo Hong filed Critical Univ Illinois
Priority to EP06770729A priority Critical patent/EP1883650A4/en
Priority to CA002608398A priority patent/CA2608398A1/en
Priority to AU2006251644A priority patent/AU2006251644A1/en
Priority to BRPI0612431-3A priority patent/BRPI0612431A2/en
Priority to JP2008512556A priority patent/JP2008545398A/en
Priority to MX2007014599A priority patent/MX2007014599A/en
Publication of WO2006127514A2 publication Critical patent/WO2006127514A2/en
Priority to IL187160A priority patent/IL187160A0/en
Priority to NO20076389A priority patent/NO20076389L/en
Publication of WO2006127514A3 publication Critical patent/WO2006127514A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/80—Cytochromes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to cupredoxin, specifically Pseudomonas aeruginosa azurin, and/or Pseudomonas aeruginosa cytochrome c551 and their use in inhibiting of viral infection, and in particular infection of mammalian cells by the Human Immunodeficiency Virus (HIV). The invention also relates to variants and derivatives of cupredoxin and cytochrome c that retain the ability to inhibit viral infection, and in particular infection by the Human Immunodeficiency Virus (HIV). The invention also relates to research methods for studying viral and bacterial infection in mammalian cells.
PCT/US2006/019565 2005-05-20 2006-05-19 Compositions and methods for treating hiv infection with cupredoxin and cytochrome c WO2006127514A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP06770729A EP1883650A4 (en) 2005-05-20 2006-05-19 Compositions and methods for treating hiv infection with cupredoxin and cytochrome c
CA002608398A CA2608398A1 (en) 2005-05-20 2006-05-19 Compositions and methods for treating hiv infection with cupredoxin and cytochrome c
AU2006251644A AU2006251644A1 (en) 2005-05-20 2006-05-19 Compositions and methods for treating HIV infection with cupredoxin and cytochrome c
BRPI0612431-3A BRPI0612431A2 (en) 2005-05-20 2006-05-19 compositions and methods for the treatment of hiv infection with cupredoxin and cytochrome c
JP2008512556A JP2008545398A (en) 2005-05-20 2006-05-19 Compositions and methods for treating HIV infection using cupredoxin and cytochrome C
MX2007014599A MX2007014599A (en) 2005-05-20 2006-05-19 Compositions and methods for treating hiv infection with cupredoxin and cytochrome c.
IL187160A IL187160A0 (en) 2005-05-20 2007-11-05 Compositions and methods for treating hiv infection with cupredoxin and cytochrome c
NO20076389A NO20076389L (en) 2005-05-20 2007-12-11 Compositions and methods for treating HIV infection with cupredoxin and cytochrome C

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US68283305P 2005-05-20 2005-05-20
US60/682,833 2005-05-20
US11/244,105 2005-10-06
US11/244,105 US7691383B2 (en) 2004-10-07 2005-10-06 Cupredoxin derived transport agents and methods of use thereof
US78086806P 2006-03-10 2006-03-10
US60/780,868 2006-03-10

Publications (2)

Publication Number Publication Date
WO2006127514A2 WO2006127514A2 (en) 2006-11-30
WO2006127514A3 true WO2006127514A3 (en) 2008-06-26

Family

ID=37452656

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/019565 WO2006127514A2 (en) 2005-05-20 2006-05-19 Compositions and methods for treating hiv infection with cupredoxin and cytochrome c

Country Status (10)

Country Link
EP (1) EP1883650A4 (en)
JP (1) JP2008545398A (en)
KR (1) KR20080024124A (en)
AU (1) AU2006251644A1 (en)
BR (1) BRPI0612431A2 (en)
CA (1) CA2608398A1 (en)
IL (1) IL187160A0 (en)
MX (1) MX2007014599A (en)
NO (1) NO20076389L (en)
WO (1) WO2006127514A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491394B2 (en) 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
EP1904642A4 (en) 2005-07-19 2008-11-26 Univ Illinois Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof
WO2007024368A2 (en) * 2005-07-19 2007-03-01 The Board Of Trustees Of The University Of Illinois Compositions and methods to control angiogenesis with cupredoxins
CA2671492A1 (en) * 2006-12-04 2008-06-12 The Board Of Trustees Of The University Of Illinois Compositions and methods to treat cancer with cupredoxins and cpg rich dna

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030081445A (en) * 2001-02-15 2003-10-17 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 Cytotoxic factors for modulating cell death
US7491394B2 (en) * 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
KR20080019615A (en) * 2005-05-20 2008-03-04 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 Compositions and methods for treating malaria with cupredoxin and cytochrome

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HIRAOKA Y. ET AL.: "Modulation of mammalian cell growth and death by prokaryotic and eukaryotic cytochrome", P.N.A.S., vol. 101, no. 17, April 2004 (2004-04-01), pages 6427 - 6432, XP002525219 *
YAMADA T. ET AL.: "Apoptosis or growth arrest: Modulation of tumor suppressor p53's specificity by bacterial redox protein azurin", P.N.A.S., vol. 101, no. 14, April 2004 (2004-04-01), pages 4770 - 4775, XP002525224 *

Also Published As

Publication number Publication date
NO20076389L (en) 2008-02-20
CA2608398A1 (en) 2006-11-30
EP1883650A2 (en) 2008-02-06
EP1883650A4 (en) 2009-06-10
WO2006127514A2 (en) 2006-11-30
BRPI0612431A2 (en) 2009-02-10
JP2008545398A (en) 2008-12-18
KR20080024124A (en) 2008-03-17
IL187160A0 (en) 2008-02-09
AU2006251644A1 (en) 2006-11-30
MX2007014599A (en) 2008-02-07

Similar Documents

Publication Publication Date Title
EP1907000B8 (en) Methods and compositions for the treatment of persistent HIV infections by inhibiting the programmed cell death 1 (PD-1) pathway
WO2008127364A3 (en) Antiviral compounds and use thereof
WO2007022371A3 (en) Chemokine receptor binding compounds
WO2009026179A3 (en) Antiinfective proanthocyanidin compounds and methods of use thereof
WO2006066079A3 (en) Pyridazinone compounds
WO2008115281A3 (en) Compounds for treating viral infections
WO2010030538A3 (en) Compounds for the treatment of hepatitis c
WO2009129470A3 (en) Methods for treating herpes virus infections
WO2008036932A3 (en) Compositions and methods comprising boswellia species
UA93384C2 (en) Process for manufacture of sterilized powder pancreatin
WO2007041632A3 (en) Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection
DE602005012276D1 (en) USE OF PROBIOTIC BACTERIA FOR THE PREPARATION OF TOPICAL COMPOSITIONS FOR THE PROTECTION OF THE SKIN
WO2007131072A3 (en) Hydrolytically-resistant boron-containing therapeutics and methods of use
WO2009029384A3 (en) Compounds for the treatment of hepatitis c
WO2006081554A3 (en) Phenyl-substituted pyrrolidones
WO2008133704A3 (en) Antimicrobial and antiviral compounds and methods for their use
WO2007024628A3 (en) Ply-gbs mutant lysins
WO2008073982A3 (en) 5,6-dihydro-1h-pyridin-2-one compounds
CA2556829C (en) Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
WO2004037784A3 (en) Pyrrolidones with anti-hiv activity
WO2009036341A3 (en) Compositions and methods relating to hiv protease inhibition
WO2008132021A3 (en) Fungicide mixtures
WO2006130426A3 (en) Modulators of ccr-5 activity
WO2006127514A3 (en) Compositions and methods for treating hiv infection with cupredoxin and cytochrome c
WO2010052575A3 (en) Ngna compositions and methods of use

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680017472.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 187160

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2006251644

Country of ref document: AU

Ref document number: 563349

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2608398

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1908/MUMNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006770729

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008512556

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/014599

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1020077028986

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2007147471

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0612431

Country of ref document: BR